|
|
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) |
|
Price: $9.5700
$0.39 
4.248%
|
| Day's High:
| $9.6899995803833
| Week Perf:
| 8.75 %
|
| Day's Low: |
$ 9.04 |
30 Day Perf: |
9.37 % |
| Volume (M): |
1,211,483 |
52 Wk High: |
$ 18.31 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$12.24 |
| Open: |
$9.17 |
52 Wk Low: |
$8.21 |
|
|
| Market Capitalization (Millions $) |
785 |
| Shares
Outstanding (Millions) |
82 |
| Employees |
371 |
| Revenues (TTM) (Millions $) |
205 |
| Net Income (TTM) (Millions $) |
-157 |
| Cash Flow (TTM) (Millions $) |
-31 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Phathom Pharmaceuticals Inc. is a biopharmaceutical company that focuses entirely on the development and commercialization of treatments for gastrointestinal diseases. The company was founded in 2018 and is headquartered in Buffalo Grove, Illinois. The company aims to improve the lives of patients suffering from gastrointestinal diseases, which are often challenging to diagnose and treat.
Phathom is driven by its mission to provide innovative treatments and medical solutions, which are based on deep scientific and clinical understanding of gastrointestinal diseases. The company's expertise is demonstrated by its current product portfolio, which includes two FDA-approved treatments for gastrointestinal diseases.
The first product, Omeprazole Magnesium-antazoline Sodium, is a combination therapy for the treatment of gastroesophageal reflux disease (GERD) and other acid-related conditions. This product is intended for patients who are unresponsive to conventional treatment options. The second product, Vonoprazan, is a proton pump inhibitor (PPI) that is used to treat GERD and for the prevention of gastric ulcers. Both products are highly effective and have helped many patients manage their symptoms and improve their quality of life.
In addition to its existing product portfolio, Phathom is also investing in the development of novel treatments for gastrointestinal diseases. The company has a deep pipeline of potential treatments that are currently in various stages of development, including treatments for Helicobacter pylori infection and eosinophilic esophagitis. The company's pipeline is highly promising, and many of its potential treatments have shown promising results in clinical trials.
Phathom has a highly experienced and skilled management team that is led by Dr. Azmi Nabulsi, who serves as the CEO. The company also has a strong group of investors, including leading venture capital firms and institutional investors. With its deep scientific understanding of gastrointestinal diseases, strong product portfolio, and promising pipeline, Phathom Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry for the treatment of gastrointestinal diseases.
Company Address: 100 Campus Drive Florham Park 7932 NJ
Company Phone Number: 742-8466 Stock Exchange / Ticker: NASDAQ PHAT
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Fri, Jun 6 2025 5:06 PM UTC
Gastroesophageal reflux disease (GERD) is a chronic condition characterized by the backflow of stomach contents into the esophagus, causing symptoms such as heartburn, chest pain, and regurgitation. Among its various forms, Erosive GERD (EGD), which leads to inflammation and damage of the esophageal lining, poses significant treatment challenges. The introduction of innovati...
|
| Stock Market Announcement
Published Thu, May 1 2025 8:16 PM UTC
In a significant strategic maneuver, Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company dedicated to advancing treatments for gastrointestinal (GI) diseases, announced the appointment of Jonathan Bentley as Senior Vice President, Head of Sales. This pivotal decision is part of a broader initiative to enhance the company s market engagement and patient ...
|
| Product Service News
Published Mon, Dec 30 2024 1:13 AM UTC
Phathom Pharmaceuticals, Inc. a biopharmaceutical company focused on advancing novel treatments for gastrointestinal (GI) diseases, has taken a decisive step to protect its innovative drug, VOQUEZNA (vonoprazan), by submitting a Citizen Petition (CP) to the U.S. Food and Drug Administration (FDA). Announced on December 11, 2024, the petition requests a revision in the Orange...
|
| Shares
Published Mon, Aug 19 2024 12:00 PM UTC
Florham Park, N.J. - August 19, 2024 - Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a leading biopharmaceutical company specializing in groundbreaking treatments for gastrointestinal diseases, has just announced the pricing of its underwritten offering. This offering consists of 8,695,652 shares of common stock and pre-funded warrants to purchase 2,608,922 shares ...
|
| Announcement
Published Wed, May 15 2024 12:01 PM UTC
Phathom Pharmaceuticals to Present Groundbreaking Data on VOQUEZNA (vonoprazan) at DDW 2024 Annual MeetingFLORHAM PARK, N.J., May 15, 2024 - Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a leading biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal (GI) diseases, has recently unveiled plans to showcase...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.91 $ |
| Revenues (TTM) |
2.5 $
|
| Cash Flow (TTM) |
- |
| Cash |
2.2 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
552,270 |
| Net
Income per Employee (TTM) |
-423,989 |
| Receivable Turnover Ratio (TTM) |
3.08 |
| Inventory Turnover Ratio (TTM) |
6.48 |
| Asset Turnover Ratio (TTM) |
0.78 |
|
|
| Per Share |
|
| Earnings (TTM) |
0.91 $
|
| Revenues (TTM) |
2.5 $ |
| Cash Flow (TTM) |
- |
| Cash |
2.2 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| VOQUEZNA Product |
|
 100 % |
of total Revenue |
| Reportable Aggregation before Other Segment |
|
100 % |
of total Revenue |
|
|
3.19%